Literature DB >> 29791793

Assays for Nucleotide Competitive Reversible and Irreversible Inhibitors of Ras GTPases.

Sadasivam Jeganathan1, Matthias P Müller2, Imtiaz Ali1, Roger S Goody1.   

Abstract

Although the Ras protein has been seen as a potential target for cancer therapy for the past 30 years, there was a tendency to consider it undruggable until recently. This has changed with the demonstration that small molecules with a specificity for (disease related mutants of) Ras can indeed be found, and some of these molecules form covalent adducts. A subgroup of these molecules can be characterized as competing with binding of the natural ligands GTP and GDP. Because of the distinct properties of Ras and related GTPases, in particular the very high nucleotide affinities and associated very low dissociation rates, assays for characterizing such molecules are not trivial. This is compounded by the fact that Ras family GTPases tend to be thermally unstable in the absence of a bound nucleotide. Here, we show that instead of using the unstable nucleotide-free Ras, the protein can be isolated as a 1:1 complex with a modified nucleotide (GDP-β-methyl ester) with low affinity to Ras. With this nucleotide analogue bound to the protein, testing of inhibitors is made experimentally more convenient and we present assays that allow the rapid assessment of the kinetic constants describing the inhibition process.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29791793     DOI: 10.1021/acs.biochem.8b00234

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  1 in total

1.  Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants.

Authors:  Imran Khan; Akiko Koide; Mariyam Zuberi; Gayatri Ketavarapu; Eric Denbaum; Kai Wen Teng; J Matthew Rhett; Russell Spencer-Smith; G Aaron Hobbs; Ernest Ramsay Camp; Shohei Koide; John P O'Bryan
Journal:  Cell Rep       Date:  2022-02-08       Impact factor: 9.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.